Biologicals in india are not a good business. Adalimumab is a low margin business with heavy competition. This will be good if they get into Exports. But then registrations are lot more expensive.
Don’’t think if people in biologicals in India are making big money. Especially MABs
| Subscribe To Our Free Newsletter |
